Sign in
TerminatedPhase 2

A Pharmaco-imaging Approach to Predicting Social Functioning and Clinical Responses to Oxytocin Administration in Schizophrenia

Key facts

Who runs it
VA Office of Research and Development
Where
San Francisco and West Los Angeles, United StatesSee the 2 sites
Trial code
Status
Terminated
Phase
Phase 2
People taking part
26 people enrolled
Started
13 Jan 2020
Ended
31 Jan 2024
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Oxytocin
  • Placebo
Record updated
20 January 2026
Why it stopped
Inadequate Subject Recruitment

Who can take part

Age
18 years to 70 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Veteran
  • age 18-70
  • a diagnosis of schizophrenia, schizophreniform, schizoaffective, or brief psychotic disorder determined by the Structured Clinical Interview for DSM-5
  • no medication changes or psychiatric hospitalizations in the past month
  • SFS modified raw score of no more than 75

Who cannot take part

  • currently taking high dose testosterone or estrogen/progesterone
  • substance use disorder in the past month, except mild to moderate cannabis use disorder
  • illness affecting the nasal passages
  • significant neurological/medical disorder
  • pacemakers
  • extensive dental work
  • claustrophobia
  • deafness
  • inability to read
  • currently participating in a psychosocial intervention targeting social functioning deficits
  • inability to complete VOT

Where in United States

  • San Francisco VA Medical Center, San Francisco, CASan Francisco, United States
  • VA Greater Los Angeles Healthcare System, West Los Angeles, CAWest Los Angeles, United States

About the trial

What the trial wants to find out

Schizophrenia has a devastating and disproportionate effect on veterans compared to the general US population. Some of the most disabling symptoms, such as low motivation, difficulty expressing emotions, and decreased ability to infer the mental states of others, cause poor social functioning. This means that veterans with schizophrenia have trouble navigating interpersonal interactions and building meaningful relationships in the community. Unfortunately, current antipsychotic medications typically only improve positive symptoms but fail to improve social functioning deficits, which are strong predictors of poor quality of life and functional outcomes. Oxytocin, a peptide found in the brain, plays an important role in social behavior and is known to moderate affiliation, stress, and learning across taxa. In this study, the investigators will test whether oxytocin could be an effective treatment for social functioning deficits in schizophrenia. The investigators will examine changes in brain activation to understand how oxytocin affects behavior and to predict which individuals may benefit from oxytocin treatment.

The 2 groups in the trial

  • Intranasal OxytocinTreatment being tested

    Dosages of oxytocin: 20IU or 40IU.

    Treatment: Oxytocin

  • PlaceboPlacebo, for comparison

    Saline

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
20 January 2026